American Century Companies Inc. Purchases 6,023 Shares of Quanterix Co. (NASDAQ:QTRX)

American Century Companies Inc. raised its position in Quanterix Co. (NASDAQ:QTRX) by 9.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 71,992 shares of the company’s stock after purchasing an additional 6,023 shares during the period. American Century Companies Inc.’s holdings in Quanterix were worth $765,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in QTRX. William Blair Investment Management LLC bought a new position in shares of Quanterix during the fourth quarter valued at approximately $11,290,000. Valmark Advisers Inc. raised its holdings in Quanterix by 88.3% in the fourth quarter. Valmark Advisers Inc. now owns 210,878 shares of the company’s stock worth $2,242,000 after purchasing an additional 98,883 shares in the last quarter. Graypoint LLC purchased a new stake in Quanterix during the fourth quarter valued at approximately $691,000. Raymond James Financial Inc. acquired a new stake in shares of Quanterix in the 4th quarter worth $570,000. Finally, JPMorgan Chase & Co. raised its position in shares of Quanterix by 28.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 217,957 shares of the company’s stock valued at $2,825,000 after purchasing an additional 47,873 shares during the last quarter. Institutional investors own 86.48% of the company’s stock.

Quanterix Trading Up 8.1 %

Shares of QTRX stock opened at $5.20 on Friday. The company has a market capitalization of $201.64 million, a P/E ratio of -4.91 and a beta of 1.35. The business’s 50 day moving average is $7.09 and its two-hundred day moving average is $10.01. Quanterix Co. has a 12-month low of $4.67 and a 12-month high of $19.71.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The firm had revenue of $35.16 million for the quarter, compared to analysts’ expectations of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, research analysts predict that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Scotiabank restated an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th. Canaccord Genuity Group decreased their price objective on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.